Emerging and Established Nonsurgical Treatment Options


Darrell S. Rigel, MD, talks through the pros, cons, and unknowns of established medications such as Hedgehog inhibitors and newly FDA-approved drugs such as cemiplimab (Libtayo; Sanofi and Regeneron Pharmaceuticals). Get the latest on dosing, drug holidays, tolerability, and long-term disease management.

Related Videos
© 2023 MJH Life Sciences

All rights reserved.